

Jonathan E Schoenhals

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6587537/publications.pdf>

Version: 2024-02-01

21
papers

1,021
citations

516710

16
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

1685
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. <i>Advances in Radiation Oncology</i> , 2021, 6, 100692.	1.2	18
2	Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. , 2020, 8, e000537.		105
3	Bone morphogenetic protein 7 promotes resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 4840.	12.8	25
4	Stereotactic Ablative Radiation Therapy (SABR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 367-375.	0.8	65
5	IDO1 Inhibition Overcomes Radiation-Induced “Rebound Immune Suppression” by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 903-912.	0.8	39
6	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 193.	4.8	105
7	Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. <i>Clinical Cancer Research</i> , 2019, 25, 7576-7584.	7.0	51
8	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 599-599.	1.6	0
9	DC-HIL/Gpmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR).. <i>Journal of Clinical Oncology</i> , 2019, 37, e14129-e14129.	1.6	0
10	Radiation therapy and immunotherapy: what is the optimal timing or sequencing?. <i>Immunotherapy</i> , 2018, 10, 299-316.	2.0	49
11	Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2170.	4.8	48
12	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-“PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018, 24, 5735-5743.	7.0	48
13	Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. <i>Cancer Letters</i> , 2018, 431, 54-63.	7.2	50
14	Optimizing Radiotherapy with Immunotherapeutic Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 53-71.	1.6	10
15	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , 2017, 77, 839-850.	0.9	195
16	Genome Sequences of 19 Novel <i>Erwinia amylovora</i> Bacteriophages. <i>Genome Announcements</i> , 2017, 5, .	0.8	22
17	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 130-137.	2.0	37
18	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 257-266.	2.0	38

#	ARTICLE	IF	CITATIONS
19	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
20	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	2.0	83
21	Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Translational Lung Cancer Research, 2007, 6, 148-158.	2.8	33